**EUROlinkCAT Protocol** **for a European population-based data linkage study investigating the survival, morbidity and education of children with congenital anomalies**

Joan K Morris1, Ester Garne2, Maria Loane3, Ingeborg Barišić4, James Densem5, Anna Latos-Bieleńska6, Amanda Neville7, Anna Pierini8, Judith Rankin9, Anke Rissmann10, Hermien E.K. de Walle11, Joachim Tan1, Joanne Given3, Hugh Claridge1

1. Population Health Research Institute, St George’s, University of London, UK
2. Hospital Lillebaelt Kolding, Region Syddanmark, Denmark
3. Faculty of Life and Health Sciences, Ulster University, Northern Ireland, UK
4. Klinika za dječje bolesti Zagreb, Croatia
5. Biomedical Computing Limited, Battle, United Kingdom
6. Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Poznań, Poland
7. IMER Registry (Emila Romagna Registry of Birth Defects), University Hospital of Ferrara, Italy
8. National Research Council-Institute of Clinical Physiology (Consiglio Nazionale delle Ricerche-Istituto di Fisiologia Clinica), Pisa, Italy
9. Population Health Sciences Institute, Newcastle University, UK
10. Malformation Monitoring Centre Saxony-Anhalt, Medical Faculty Otto-von-Guericke-University Magdeburg, Magdeburg, Germany
11. University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, the Netherlands

Correspondence to Joan K Morris; jmorris@sgul.ac.uk

Word count: 5542

Keywords: Protocol; Congenital Anomalies; Linkage; Mortality; Morbidity

# Abstract

## Introduction

Congenital anomalies (CA) are a major cause of infant mortality, childhood morbidity and long-term disability. Over 130,000 children born in Europe every year will have a CA. This paper describes the EUROlinkCAT study, which is investigating the health and educational outcomes of children with CAs for the first 10 years of their lives.

## Methods and analysis

EUROCAT is a European network of population-based registries for the epidemiological surveillance of CAs. EUROlinkCAT is using the EUROCAT infrastructure to support 22 EUROCAT registries in 14 countries to link their data on births with CAs to mortality, hospital discharge, prescription and educational databases. Once linked, each registry transforms their case data into a Common Data Model (CDM) format and they are then supplied with common STATA syntax scripts to analyse their data. The resulting aggregate tables and analysis results are submitted to a Central Results Repository (CRR) and meta-analyses are performed to summarise the results across all registries. The CRR currently contains data on 155,594 children with a CA followed up to age 10 from a population of 6 million births from 1995 to 2014.

## Ethics

The CA registries have the required ethics permissions for routine surveillance and transmission of anonymised data to the EUROCAT central database. Each registry is responsible for applying for and obtaining additional ethics and other permissions required for their participation in EUROlinkCAT.

## Dissemination

The CDM and associated documentation, including linkage and standardisation procedures, will be available post-EUROlinkCAT thus facilitating future local, national and European-level analyses to improve health care. Recommendations to improve the accuracy of routinely collected data will be made.

Findings will provide evidence to inform parents, health professionals, public health authorities and national treatment guidelines to optimise diagnosis, prevention and treatment for these children with a view to reducing health inequalities in Europe.

# Article summary

## Strengths and limitations of this study

* The implementation of a common data model enables the same centrally developed syntax script to be run in all registries which is efficient and ensures standardisation of analysis.
* The use of a reference population allows country differences to be adjusted for and enables more accurate comparisons of the burden of disease attributable to congenital anomalies across countries to be made.
* Merging births with congenital anomalies to their records in routine health care data enables a detailed evaluation of the accuracy of the data and enables improvements to be suggested.
* Being unable to share individual case data or aggregate data that might be disclosive reduces the power of the analysis that can be performed, particularly for rare anomalies.
* Only specific areas in Europe are represented, with a lack of data in particular from Eastern Europe.

# Introduction

Over 130,000 children born in Europe every year will have a major CA, equivalent to 2.5% of all European births. CAs include structural defects, chromosomal anomalies and genetic syndromes. CAs are a leading cause of perinatal and infant mortality, especially in developed countries [1]. From 2003 to 2012, CAs were associated with about 40% of all infant deaths in Sweden and England [2]. There is a large variation in child death rates across Europe; in 2013 the child death rates (age 0-14 years) were 60% higher in the UK and Belgium compared to Sweden, with an additional 10 countries being 30% higher than Sweden [3]. To identify potentially preventable and remedial causes it is important to investigate the health inequalities in survival in children with CA across Europe.

It has been shown that relying on death certificates as a source of information on mortality due to CAs does not provide an accurate assessment of the survival for children with specific CAs. Death certificates state the direct or primary cause of death which may be infection, seizures or others and therefore may not mention the CA[4]. Copeland et al. (2007)[4] concluded that the only way to accurately study mortality and survival in children with rare CAs is to pool data across CA registries and link these to death registries.

Advances in fetal, neonatal and paediatric care have improved outcomes for individuals with some CAs, for example Down syndrome[5-7] and cardiac anomalies. Several studies have shown that children with CAs account for a very high proportion of all hospital admissions [8, 9]. However, there is a lack of information on the length of hospital stays for children with specific CAs, with most studies concerning children with Down syndrome, orofacial clefts or congenital heart defects (CHD) [10]. Often hospital stays are investigated for the first two or three years of a child’s life[11-14]. However, Wehby *et al*. (2012) showed that hospital admissions for those born with orofacial clefts were increased at all ages up to 60 years of age[15]. Rarely has length of hospital stay been related to other factors, such as social class. Two studies (Derrington 2013 in the USA to 3 years of age and Hung 2011 in Taiwan for all ages) both identified other factors such as ethnicity and socio-economic factors as important influences on the length of inpatient stays in children and adults with Down syndrome[12, 16].

The proportion of children born with a CA surviving beyond infancy is increasing [5, 6]. How these children are performing in school and their additional educational needs is therefore becoming increasingly important as there may be a growing population of children and young people requiring additional support and resources in the future. However, apart from the more common genetic syndromes, there is a paucity of information about this[17, 18]. The American Heart Association reviewed the literature on children with CHD and concluded that they are at an increased risk of developmental delay, even once the frequent occurrence of genetic syndromes has been taken into account, particularly for neonates or infants requiring open heart surgery[19]. Wehby *et al*. (2015) also showed that children with isolated orofacial clefts were at a much greater risk of low achievement at school than their classmates[20]. A systematic review of neurocognitive outcomes following general anaesthesia and surgery in children concluded that exposure to general anaesthesia in young children did affect their development in some neurocognitive domains [21]. However, the authors recommended that the effects of surgery should be considered separately for each specific anomaly.

EUROCAT (https://eu-rd-platform.jrc.ec.europa.eu/eurocat) is a European network of population-based CA registries, which started in 1979 and has expanded to include 39 registries in 21 countries covering more than 29% of European births (1.7 million) per year [22-24]. The main objectives of EUROCAT are to provide essential epidemiologic information and surveillance on CAs in Europe, to evaluate the effectiveness of primary prevention and to assess the impact of developments in prenatal screening[25, 26]. Hence the emphasis is on information collected up to a baby’s first year of life.

The aim of EUROlinkCAT is to investigate the survival, morbidity and educational outcomes of children with specific CAs for the first 10 years of their lives by linking births with CAs in EUROCAT registries to electronic health care and education databases. The availability of population-based data on births with CAs across the EUROCAT network will enable survival, morbidity and education to be investigated for specific CAs as well as differences in these outcomes across Europe according to specific risk factors and social inequalities to be explored.

Electronic health care data are increasingly being used by researchers to investigate the epidemiology of CAs, rather than using information from CA registries. Such health care data have often been found to be incomplete[27-31]. A small number of registries will analyse the maternal pregnancy records for women registered as having had a termination of pregnancy for a fetal anomaly (TOPFA) in EUROCAT. This will enable the accuracy of routine information on TOPFAs to be evaluated. The accuracy of CA coding in live births will be evaluated by comparing the EUROCAT data for live births with the CA diagnosis from the electronic health care databases covering both in-patient and out-patient visits. The information on death certificates will be compared to the anomalies recorded in EUROCAT. Recommendations will be developed to enable the maximum information from electronic health care data to be extracted for research purposes and to quantify the amount of data that cannot be obtained.

This paper describes the design of the study, the methods used to obtain and analyse the linked data and evaluates the first three years’ progress of EUROlinkCAT.

# Methods and analysis

## Design and Setting

In 2017, all EUROCAT registries were invited to participate in the EUROlinkCAT study. Twenty-two registries from 14 countries agreed to participate and to link all live births with a CA registered in their registries and born from 1st January 1995-31st December 2014. Almost all EUROCAT registries send anonymised data on CAs occurring in all livebirths, fetal deaths from 20 weeks gestation and TOPFAs to the EUROCAT central database. Comprehensive coding instructions [32] and the use of the EUROCAT Data Management Program (EDMP) to import data into the central database ensure that standard variables, definitions and coding are used by all registries in the network. CAs are coded locally using the WHO International Statistical Classification of Diseases and Related Health Problems (ICD) 9th or 10th Revision with the British Paediatric Association (BPA) code extension offering more specificity (Table 1). Cases with minor anomalies only are excluded (see EUROCAT Guide 1.4, Minor Anomalies for Exclusion (version 14.10.14)). Registries can code up to nine anomalies for each case and provide additional information in the specified text fields. Based on the ICD-9 or ICD-10 codes present, cases are automatically assigned by EDMP to defined major CA subgroups in accordance with the EUROCAT guide 1.4. A case with more than one major anomaly may be assigned to more than one subgroup. Since 2015, the central database has been hosted by the European Commission Joint Research Centre in Ispra (Italy).

Tables 1 and 2 provide a list of the 81 EUROlinkCAT CA subgroups which include structural anomalies, genetic syndromes and chromosomal anomalies that will be investigated. There are 60 EUROCAT subgroups (Table 1) and an additional 21 new CA subgroups not defined in EUROCAT (Table 2). The subgroups have been identified as being reasonably homogeneous to provide meaningful information and also to be prevalent enough to enable sufficiently precise estimates to be obtained from the analyses. For example, the EUROCAT subgroup “Chromosomal” was not included as it includes all genetic syndromes, but specific syndromes such as Down syndrome (a EUROCAT subgroup) and Di George syndrome (a new subgroup) were included. For some analysis, such as mortality, Down syndrome children will be analysed according to whether they have a cardiac anomaly and/or a gastrointestinal anomaly, as these are common and are likely to influence their survival. As outcomes are expected to be more severe for children with multiple and more complex CAs, analyses are also performed separately for children with isolated anomalies or with multiple anomalies defined according to the methodology by Garne et al.[33] . Isolated anomalies are defined as a CA in one organ system only or with a known sequence where multiple CAs cascade as a consequence of a single primary anomaly. Multiple anomalies are defined as two or more major structural CAs in different organ systems, where the pattern of anomalies has not been recognised as part of a syndrome or sequence.

Table 1: EUROCAT congenital anomaly subgroups in EUROlinkCAT

|  |  |  |
| --- | --- | --- |
| **EUROCAT Subgroups** | **ICD-10-BPA** | **ICD-9-BPA** |
| **All anomalies \*** | Q-chapter, D215, D821, D1810^, P350, P351, P371 | 74, 75, 27910, 2281^, 76076, 76280, 7710, 7711, 77121 |
| **Structural anomalies** |  |  |
|  Spina Bifida | Q05 | 741 |
|  Hydrocephalus | Q03 | 7423  |
|  Severe microcephaly | Q02 | 7421 |
|  Congenital cataract | Q120 | 74332 |
| Congenital Heart Defects (CHD) | Q20-Q26 | 745, 746, 7470-7474 |
|  Severe CHD | Q200, Q201, Q203, Q204, Q212, Q213, Q220, Q224, Q225, Q226, Q230, Q232, Q233, Q234, Q251, Q252, Q262 | 74500, 74510, 7452, 7453, 7456, 7461, 7462, 74600, 7463, 7465, 7466, 7467, 7471, 74720, 74742 |
|  Transposition of great vessels | Q203 | 74510 |
|  Ventricular Septal Defect | Q210 | 7454 |
|  ASD | Q211 | 7455 |
|  AVSD | Q212 | 7456 |
|  Tetralogy of Fallot | Q213 | 7452 |
|  Pulmonary valve stenosis | Q221 | 74601 |
|  Aortic valve atresia/stenosis | Q230 | 7463 |
|  Mitral valve anomalies | Q232, Q233 | 7465, 7466 |
|  Hypoplastic left heart | Q234 | 7467 |
|  Coarctation of aorta | Q251 | 7471 |
|  Patent ductus arteriosus (PDA) as only CHD in term infants (GA +37 weeks) | Q250 | 7470 |
|  Cystic adenomatous malformation of lung | Q3380 | No code |
|  Cleft lip with or without cleft  palate | Q36, Q37 | 7491, 7492 |
|  Cleft palate | Q35 | 7490 |
|  Oesophageal atresia with/ without trachea-oesophageal fistula | Q390-Q391 | 75030-75031 |
|  Duodenal atresia or stenosis | Q410 | 75110 |
|  Atresia or stenosis of other parts of small intestine | Q411-Q418 | 75111-75112 |
|  Ano-rectal atresia and stenosis | Q420-Q423 | 75121-75124 |
|  Diaphragmatic hernia | Q790 | 75661 |
|  Gastroschisis | Q793 | 75671 |
|  Omphalocele | Q792 | 75670 |
|  Multicystic renal dysplasia | Q6140, Q6141 | 75316 |
|  Congenital hydronephrosis | Q620 | 75320 |
|  Hypospadias | Q54 | 75260 |
|  Limb reduction defects | Q71-Q73 | 7552-7554 |
|  Craniosynostosis | Q750 | 75600 |
|  |  |  |
| **Chromosomal anomalies** |  |  |
|  Down syndrome  | Q90  | 7580  |
|  Trisomy 13 | Q914-Q917 | 7581 |
|  Trisomy 18 | Q910-Q913 | 7582 |
|  Turner syndrome  | Q96  | 75860, 75861, 75862, 75869  |
|  Klinefelter syndrome  | Q980-Q984  | 7587  |
|  |  |  |
| **Rare structural anomalies with a EUROCAT subgroup** |  |  |
|  Encephalocele | Q01 | 7420 |
|  Arhinencephaly / holoprosencephaly | Q041, Q042 | 74226 |
|  Anophthalmos / microphthalmos | Q110, Q111, Q112 | 7430, 7431 |
|  Anophthalmos | Q110, Q111 | 7430 |
|  Congenital glaucoma | Q150 | 74320 |
|  Anotia | Q160 | 74401 |
|  Common arterial truncus | Q200 | 74500 |
|  Double outlet right ventricle | Q201 | No code |
|  Single ventricle | Q204 | 7453 |
|  Triscuspid atresia and stenosis | Q224 | 7461 |
|  Ebstein’s anomaly | Q225 | 7462 |
|  Pulmonary valve atresia | Q220 | 74600 |
|  Hypoplastic right heart | Q226 | No code |
|  Aortic atresia / interrupted aortic arch | Q252 | 74720 |
|  Total anomalous pulmonary venous return | Q262 | 74742 |
|  Choanal atresia | Q300 | 7480 |
|  Hirschsprung’s disease | Q431 | 75130-75133 |
|  Atresia of bile ducts | Q442 | 75165 |
|  Annular pancreas | Q451 | 75172 |
|  Indeterminate sex | Q56 | 7527 |
|  Situs inversus | Q893 | 7593 |
|  VATER/VACTERL | Q8726 | 759895 |

\* All Anomalies = ALL cases of congenital anomaly, excluding cases with only minor anomalies as defined in Section 3.2 in EUROCAT Guide 1.4 for cases born post-2005. Cases with more than one anomaly are only counted once in the “All Anomalies” subgroup.

^ ICD10 code D1810 (ICD 9 code 2281) is the code for cystic hygroma

Table 2: New congenital anomaly subgroups in EUROlinkCAT

|  |  |  |
| --- | --- | --- |
| **New subgroups for EUROlinkCAT** | **ICD-10-BPA** | **ICD-9-BPA†** |
|  |  |  |
| Structural anomalies |  |  |
| Anomalies of corpus callosum | Q040 | 74221 |
| Anomalies of intestinal fixation | Q433 | 7514 |
| Unilateral renal agenesis | Q600 | No code |
| Accessory kidney | Q630 | 75330 |
| Bladder exstrophy  | Q641 | 7535 |
| Epispadia | Q640 | 75261 |
| Posterior urethral valves | Q6420 | 75360 |
| Prune Belly | Q794 | 75672 |
| Arthrogryposis multiplex congenita | Q743 | 75580 |
|  |  |  |
| Genetic syndromes |  |  |
| Di George syndrome  | D821 | 27910 |
| Goldenhar syndrome | Q8704 | 75606 |
| Cornelia de Lange syndrome | Q8712 | 759821 |
| Noonan syndrome | Q8714 | 759896 |
| Prader-Willi | Q8715 | 759872 |
| Beckwith-Wiedemann syndrome | Q8730 | 759874 |
| Williams syndrome | Q8784 | No code |
| Angelman syndrome | Q8785 | No code |
|  |  |  |
| Chromosomal anomalies |  |  |
| Wolff-Hirschhorn syndrome | Q933 | 75832 |
| Cri-du chat syndrome | Q934 | 75831 |
| Karyotype XXX | Q970 | 75885 |
|  |  |  |
| Sequences |  |  |
| Pierre-Robin sequence | Q8708 | 75603 |

## Linkage

Table 3 provides details of the linkages originally planned by the EUROCAT registries and the current linkages occurring (as of August 2020). The reasons why some registries could not link their data are explored in detail in another paper submitted for publication - they include not being able to obtain the necessary permissions, relevant outcomes not being recorded in specific data sources and the time scale for the data supply being after the end of the study’s funding. Currently, 19 registries are linking their data to mortality records, 15 plan to link to hospital in-patient records and seven to prescription records for the work package that will consider morbidity for children born with a CA. At the time of writing, nine registries plan to link their information on children with CAs to education records. To evaluate the accuracy of the routine health care data, five registries are additionally linking to out-patient data and four will also link to pregnancy information recorded in the mother’s health records about TOPFAs. The 19 registries survey over 6 million births in the population.

Table 3: EUROCAT Congenital anomaly registries in EUROlinkCAT: start year, births in the population up to 2014, live births with an anomaly in the study period and ability to link to mortality, health care, prescription and education data

|  |  |  |  |
| --- | --- | --- | --- |
| Congenital Anomaly Registry |  | Number of live births with an anomaly  | Linkages Occurring (Y), Not occurring (N) and Planned but no longer occurring (~~Y~~) |
| **Planned start year** | **Actual start year** | **Planned to be linked** | **Linked to mortality data by 8/2020** | **Mortality** | **Hospital Data for Child** | **Hospital Data for Mother** | **Prescriptions** | **Education** |
| **In-patient** | **Out-patient** | **In-patient** | **Out-patient** |
| Belgium: Antwerp | 1995 | 1997 | 8083 | 7865 | Y | N | N | N | N | N | N |
| Croatia: Zagreb | 1995 | 2011 | 2232 | 441† | ~~Y~~ | Y | ~~Y~~ | N | N |  | N |
| Denmark: Funen | 1995 | 1995 | 2418 | 2425 | Y | Y | Y | Y | Y | Y | Y |
| Finland | 1995 | 1995 | 44869 | 42861 | Y | Y | Y | Y | Y | Y | Y |
| France: Île de la Réunion | 2002 | NC | 3855 | NC | ~~Y~~ | ~~Y~~ | N | N | N | N | N |
| France: Paris | 1997 | 1995 | 13335 | 11623 | Y | N | N | N | N | N | N |
| Germany: Saxony-Anhalt | 1995 | 2005 | 8821 | 8698 | Y | N | N | N | N | N | N |
| Italy: Emilia Romagna | 1995 | 2008 | 11447 | 7327 | Y | Y | N | N | N | Y | Y |
| Italy: Tuscany | 1995 | 2005 | 9827 | 5187 | Y | Y | Y | N | N | Y | ~~Y~~ |
| Malta | 1995 | 2005 | 2470 | 2718 | Y | N | N | N | N | N | N |
| Netherlands: Northern | 1995 | 2005 | 8567 | 8325 | Y | Y | Y | Y | Y | Y | N |
| Norway | 1999 | 1999 | 26938 | 27201 | Y | N | N | N | N | N | N |
| Portugal: South | 1995 | 2000\* | 3425\* | 2447\* | N | Y | N | N | N | N | N |
| Spain: Basque Country | 1995 | 1995 | 4883 | 5904 | Y | ~~Y~~ | N | N | N | ~~Y~~ | N |
| Spain: Valencian Region | 2007 | 2007 | 7438 | 7389 | Y | Y | N | N | N | Y | N |
| UK: East Midlands and South Yorkshire | 1998 | AL | 18549 | AL | Y | Y | N | N | N | ~~Y~~ | Y |
| UK: Northern England | 2000 | AL | 8617 | AL | Y | Y | N | N | N | ~~Y~~ | Y |
| UK: South West England | 2005 | AL | 11671 | AL | Y | Y | N | N | N | ~~Y~~ | Y |
| UK: Thames Valley | 1995 | AL | 5142 | AL | Y | Y | N | N | N | ~~Y~~ | Y |
| UK: Wales | 1998 | 1998 | 18239 | 18128 | Y | Y | Y | Y | Y | Y | Y |
| UK: Wessex | 1995 | AL | 7771 | AL | Y | Y | N | N | N | ~~Y~~ | Y |
| Ukraine: West | 2005 | 2006 | 6166 | 5835 | Y | Y | N | N | N | N | N |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Total |  |  | 234763 | 155594† | 19 | 15 | 5 | 4 | 4 | 7 | 9 |
| ~~Y~~: Linkages are no longer planned as of August 2020†: The 441 cases in Zagreb were not included in analyses due to poor quality of the mortality linkageThe registry in Basque was unable to complete the planned linkages to hospital data due to COVID-19NC: Linkages could not be completedAL: Awaiting linkage as of August 2020\*: Values for WP4 morbidity linkage have been provided, as mortality linkage was never planned |

For the evaluation of survival and morbidity, each child will be followed-up for a maximum of ten years. This age cut-off has been chosen to enable enough children to be identified and followed-up; a longer follow-up would mean fewer children would be eligible as currently national or local electronic health care record sources often do not go back more than 10 years. For education the maximum follow-up is until the end of compulsory school age (typically 16 across participating countries), although for some registers data are only available for a shorter period of follow-up. The longer follow-up was chosen in Finland where there are no national education tests and national data on education attainment are available at the age of 15-16 (9th grade).

## Reference Population

Where possible, each registry obtained information from electronic health care records, prescription records and education records on children without a CA. The definition of these “control” cohorts will vary according to the registry, ranging from all children in the same population covered by the registry to a 10% random sample of children stratified by birth year and child’s sex. The use of such a reference population is essential in interpreting differences across countries, as it will provide information on key outcomes, such as duration of hospital stays and medication prescribing, on children without reported anomalies, which is expected to vary by country. Table 4 provides information on the reference populations being identified.

Table 4: Use of a reference population in morbidity and education analyses

|  |  |
| --- | --- |
| **Congenital Anomaly Registry** | **Reference Population** |
| Croatia: Zagreb  | Sample of children |
| Denmark: Funen | Whole Population |
| Finland | Whole Population |
| France: Île de la Réunion | Not provided |
| Italy: Emilia Romagna  | Whole Population |
| Italy: Tuscany  | 10% of population |
| Netherlands: Northern | 10% of Population |
| Portugal: South | Sample of children |
| Spain: Basque | Not provided |
| Spain: Valencian Region | Whole Population |
| UK: East Midlands and South Yorkshire | Aggregate data from population for morbidity and population sample for Education |
| UK: Northern England | Aggregate data from population for morbidity and population sample for Education |
| UK: South West England | Aggregate data from population for morbidity and population sample for Education |
| UK: Thames Valley | Aggregate data from population for morbidity and population sample for Education |
| UK: Wales | Whole Population |
| UK: Wessex | Aggregate data from population for morbidity and population sample for Education |
| Ukraine: West | No longer in morbidity study |

## Standardisation and Common Data Models

EUROCAT registries submit 96 core and non-core variables to the EUROCAT central database providing pseudonymised information on the baby and mother, diagnosis, karyotype (if known), exposure, family history, and socio-demographic details. These have already been standardised and Table 5 lists the 52 variables of which 34 are core variables and their common coding scheme that are used in the EUROlinkCAT study. In contrast, all the data obtained from linkage have to be standardised to a common format, as the health care and educational systems across Europe use different native languages and coding classification schemes. To do this, each registry provided their data dictionaries describing the variables in their local databases including the variable names, format, definitions, and coding schemes.

Table 5: Standardised variables from the EUROCAT database

|  |  |
| --- | --- |
|  | **EDMP Variables used (core variables are shaded in blue)** |
| **Baby and Mother**  |
| 1 | CENTRE | Centre Number |
| 2 | NUMLOC | Local ID of case |
| 3 | BIRTH\_DATE | Date of Birth |
| 4 | SEX | Sex |
| 5  | NBRBABY | Number of babies delivered |
| 6 | SP\_TWIN  | Specify twin type of birth, like or unlike, zygosity  |
| 7 | NBRMALF | Number of malformed in multiple set |
| 8 | TYPE | Type of birth |
| 9 | CIVREG | Civil registration status |
| 10 | WEIGHT | Birth weight |
| 11 | GESTLENGTH | Length of gestation in completed weeks |
| 12 | SURVIVAL | Survival beyond one week of age |
| 13 | DEATH\_DATE | Date of death |
| 14  | DATEMO  | Date of birth of mother  |
| 15 | AGEMO | Age of mother at delivery |
| 16 | BMI  | Maternal Body Mass Index  |
| 17  | RESIDMO  | Mother’s residence code  |
| **Diagnosis**  |
| 19 | WHENDISC  | When discovered |
| 20 | CONDISC | Condition at discovery  |
| 21 | AGEDISC  | If prenatally diagnosed, gestational age at discovery |
| 22 | FIRST PRE | First positive prenatal test |
| 24 | KARYO  | Karyotype of infant/fetus  |
| 25 | SP\_KARYO  | Specify karyotype  |
| 26\* | GENTEST  | Genetic Test  |
| 27\* | SP\_GENTEST  | Specify genetic test  |
| 28 | PM  | Post mortem examination  |
| 29 | SURGERY  | First surgery for malformation performed or planned  |
| 30 | SYNDROME  | Syndrome |
| 31 | SP\_SYNDROME  | Specify Syndrome  |
| 32 | MALFO1  | malformation |
| 33  | SP\_MALFO1  | Specify malformation  |
| 34  | MALFO2  | As MALFO1  |
| 35  | SP\_MALFO2  | Specify malformation  |
| 36  | MALFO3  | As MALFO1  |
| 37  | SP\_MALFO3  | Specify malformation  |
| 38  | MALFO4  | As MALFO1  |
| 39  | SP\_MALFO4  | Specify malformation  |
| 40  | MALFO5  | As MALFO1  |
| 41  | SP\_MALFO5  | Specify malformation  |
| 42 | MALFO6  | As MALFO1  |
| 43  | SP\_MALFO6  | Specify malformation  |
| 44  | MALFO7  | As MALFO1  |
| 45  | SP\_MALFO7  | Specify malformation  |
| 46  | MALFO8  | As MALFO1  |
| 47  | SP\_MALFO8  | Specify malformation  |
| 57 | OMIM  | OMIM code / Type of Mendelian Inheritance  |
| **Exposure and family history**  |
| 58 | ASSCONCEPT | Assisted conception (where available) |
| 59##  | OCCUPMO  | Mother’s occupation at time of conception  |
| **Sociodemographic**  |
| 91 | MATEDU | Maternal education  |
| 92\*  | SOCM  | Socioeconomic status of mother  |
| 93 \* | SOCF  | Socioeconomic status of father  |
| 94  | MIGRANT  | Migrant status  |
| **Derived variables** |  |
|  | Byear | Year of birth |
|  | birth\_type | Livebirth, Stillbirth, Spontaneous abortion, TOPFA, Not knownDefinitions of stillbirths and spontaneous abortions vary between regions. This variable recodes birth type according to EUROCAT’s specifications: cases with gestational age ≥ 20 weeks are re-coded as “stillbirths” (irrespective of the local definition of stillbirth/spontaneous abortion). |
|  | casestatus | Only cases with casestatus = 1 or 2 |
|  | al1-al114 | EUROCAT subgroups: (0 = No, 1 = Yes). Based on EUROCAT coding in Guide 1.4 |
|  | mult\_malf  | Algorithm for case classification into isolated and multiple anomalies |

## EUROCAT Guide 1.4 use ISCO-08 classifications

\* See work of the standardisation committee (viii)

Table 6 shows how the variable sex (male and female) is coded for children in the different registries with different variable names, different formats and different coding schemes. For each sub-study in EUROlinkCAT, a common data model (CDM) containing all variables required for its analyses was developed. All the EUROlinkCAT CDMs contain the variable L\_CH\_SEX, defined as “sex of child” and with a coding scheme in integer format of 1=male, 2=female, 3=Indeterminate, 9=Not known ‘.’= Not recorded or not available for study. Ulster University (UU) used the information in each registry’s data dictionary to create the new EUROlinkCAT “standardised” L\_CH\_SEX variable. UU, in collaboration with the registries, created registry-specific syntax scripts to standardise all the variables in the EUROlinkCAT CDMs. Appendices 1, 2 and 3 list all the variables included in the sub-studies (mortality, electronic health care records and prescription records).

Table 6: Coding of male or female of the live births in different linked databases in EUROlinkCAT

|  |  |  |
| --- | --- | --- |
|  |  | Code |
| **Centre** | **Variable name** | **Male** | **Female** |
| UK: Wales | DEC\_SEX\_CD | 1 | 2 |
| Germany: Saxony-Anhalt | EF306 | 1 | 2 |
| Finland | SUKUP | 1 | 2 |
| Italy: Tuscany | SESSO | 1 | 2 |
| France: Île de la Réunion | SexeDefunt | 1 | 2 |
| France: Paris | SexeDefunt | 1 | 2 |
| Netherlands: Northern | geslacht | 1 | 2 |
| Croatia: Zagreb | GENDER | M or 1 | F or 2 |
| Ukraine: West | CH\_SEX | 1 | 2 |
| Belgium: Antwerp | SEX | 1 | 2 |
| Norway | KJONN | 1 | 2 |
| UK: England | sex | 1 | 2 |
| Spain: Basque Country | SEXO | 1 | 6 |
| Spain: Valencian Region | SEXO | 1 | 6 |
| Malta | gender | M | F |
| Italy: Emilia Romagna | SEX | M | F |
| Denmark: Funen | C\_SEX | M | K |

The CDMs also specify how the data are stored. For mortality, all the relevant variables occur only once for each EUROCAT case and are stored in the same data file (or table) (Figure 1). However, when analysing hospital admissions, each child may have more than one admission and for each admission may receive more than one diagnosis. Therefore, the hospital admissions data are stored in a separate data file (or table) from the diagnoses data and separately from the EUROCAT data on the child; each data file contains a reference key which serves to link all records belonging to one person for analysis (see Figure 2). The standardisation syntax scripts from UU specify the separate data files (or tables) for each linkage containing all the variables in the CDMs.

UU included validation routines in the syntax scripts to determine if the data have been correctly transformed. For example, it is checked that a date of death does not occur prior to the date of birth; whilst the primary purpose is to ensure the data have been standardised correctly, it can also reveal any errors in the linked data.

A CDM is not being defined for the linked education data as there is limited scope for comparison and pooling of data across countries. This is due in part to inherent differences in the educational stages and systems, the variability in data available, and fewer registries being able to participate (5 of the registries are from England, and 1 from Wales, Denmark, Italy and Finland).

## Work of the Standardisation Committee

In addition to defining the CDM and its structure, the EUROlinkCAT Standardisation Committee was responsible for taking other decisions, usually in consideration of local data characteristics, to ensure that data were meaningful and comparable across registries. The most important issues are listed below:

1. **Inclusion according to gestational age (GA)** **at birth**: For the mortality study all livebirths with a GA below 24 weeks were excluded, as these cases could have been miscoded terminations of pregnancy with signs of life at birth. However, after running the mortality analysis, it was noticed locally that there were survivors in EUROCAT registries at GA 23 weeks. For the morbidity studies, the exclusion criterion was lowered to be below 23 weeks.
2. **Strength of linkage**: The success of data linkage depended on the matching method and type of personal identifiers used. Where a national unique identifier (ID) was available (e.g. Denmark, Finland) over 99% of cases were matched, but success rates were generally lower when intermediary databases and a combination of other identifiers (e.g. names, postcodes) were required to establish a match, particularly if these were incomplete or incorrect. A standard way of evaluating confidence in a match had to be developed so that decisions on inclusion for analyses could be consistently made, in order to avoid bias.
3. **Gestational age groups**: The gestational age at birth was categorised into <28 weeks, 28-31 weeks, 32-36 weeks and 37+ weeks when analysing survival, but due to small numbers of survivors at under 28 weeks gestation, the two lowest gestational age categories were combined to <32 weeks.
4. **Birth weight**: Birth weight was categorised into very low birth weight ‘<1500 g’, low birth weight ‘≥1500 g to <2500 g’, normal birth weight ‘≥2500 g to 3999 g’ and high birth weight `≥4000 g’. Births <1000 g were not distinguished from those between 1000-1499 g as there were too few cases for the data to be analysed accurately.
5. **Singletons vs. multiples**: There is uncertainty about whether the survival in twins with CAs is lower than that in singletons [34-37]. Hence, all survival analyses were performed on singletons alone and then multiples and singletons combined (multiples were not analysed alone as for many registries small numbers would limit the analyses that could be performed). This enables the survival of singletons and multiples in children with CAs to be analysed in detail. When examining morbidity, multiplicity was treated as one of the risk factors for increased risk of hospitalisations and lengths of stay to enable any association to be analysed, but with less detail than for survival. The majority of analyses included singletons and multiples combined.
6. **Prenatal diagnoses**: The gestational age at prenatal diagnoses was categorised into <22 weeks, 22-31 weeks, 32+ weeks, gestational age not known and no prenatal diagnosis. For Finland, the gestational age was often not recorded, only the trimester of diagnoses. Finland’s first trimester diagnoses (week 0 to week 12) mapped exactly to the EUROlinkCAT <22 weeks category. It was decided that Finland’s 2nd trimester (week 13 to week 27) diagnoses were assumed to occur at 22-31 weeks and 3rd trimester (week 28 onwards) diagnoses occurred at 32+ weeks. These assumptions were also checked based on the distribution of those cases in Finland with a “known” age at discovery and the assumptions held.
7. **Length of stay**: The length of stay (LOS) of the child in hospital was calculated after excluding the stay associated with the birth. Methods of identifying the birth stay varied in different countries. For hospital admissions where admission and discharge occurred on the same day, the LOS was considered to be 0.5 days. If an admission record was missing a discharge date, then discharge date = date of admission + 2\*(date of latest procedure – date of admission). The date of discharge was set to the date of the child’s 10th birthday or the end of the study period if it was after either of these two dates.
8. **Socio-economic status (SES)**: All registries had different variables that could be considered to be a measure of the mother’s SES. The variables included maternal occupation, maternal education and index of multiple deprivation derived from residential codes at birth. Registries were asked to select the variable they believed was the most relevant and to re-code their selected SES proxy variable into three groups of approximately equal proportion to enable comparing between, for example, mothers in the highest group to mothers in the lowest group. The effect of SES on survival would be analysed using Cox proportional hazard models within each registry. However, only 7 registries were able to provide a proxy SES variable that was reasonably complete for some or all of the time period of the study. It was also planned to investigate the association between risk factors such as birth weight after adjusting for SES, but due to the lack of information on SES this was not included in further multivariable analyses.
9. **Maternal country of birth**: It was determined that the maternal country of birth variable would be used as a proxy for non-European ethnic origin, as we were aware that ethnic origin is poorly recorded. However, for those registries with reasonably complete data on this, almost 100% of children were reported as being of European ethnic origin. Therefore, this variable was not included in subsequent analyses as the number of children considered as “Non-European ethnic origin” was too small to analyse.
10. **Cause of death:** cause of death based on the death certificates was classified for deaths <1 year and for 1-9 years separately. Death related to preterm birth is very common in the first year after birth, but not as relevant to children at 1-9 years of age. Injuries and poisoning are more common after the first year. The main causes of deaths were classified into 6 groups for deaths <1 year and 11 groups for children aged 1-9 years. When working with the results tables it was clear that many of these classification groups included many small numbers and data could not be extracted from the databases. For some registries it was only possible to give cause of death as either “congenital anomaly” or else “any other cause of death”.
11. **Surgery**: A number of different coding systems were used across registries to code surgeries and other procedures (e.g. NCSP by NOMESCO, ICD-9-CM, OPCS-4). Frequency lists for all codes describing surgeries and other procedures were obtained from the linked datasets. Two paediatricians then independently determined if a code was a surgery or for another procedure and then a consensus between the two clinicians was reached over codes classified as codes for surgeries. Further sub-division into anomaly-specific surgeries was carried out for anomalies for which specific surgeries could be identified that would be expected to be performed on these children.
12. **Intensive care**: It was planned to analyse the number of days in intensive care, however only five registries could provide this. Therefore, only whether a child had ever been admitted to intensive care was analysed rather than their length of stay.
13. **Ventilation**: It was planned to analyse the number of days on ventilation. However, as it was decided that the length of stay in intensive care was not going to be analysed, the same decision was made for ventilation and only whether a child had ever been on ventilation was analysed.

## Assessment of Quality of Linkage and Quality of Linked Data

Many registries linked their data to National Vital Statistics, which are databases that record all live births with follow up until the child dies or emigrates outside the country/region of interest. Therefore, for these registries for the survival analysis, any child whose record was not in the National Vital Statistics Database was judged to be a non-match and overall linkage could be assessed. Some registries were only able to link to death certificates which meant that a non-match, i.e. no death certificate found, was assumed to indicate that the child was still alive. The data from these registries were only included in the survival analyses if there was additional information about the quality of the linkage. For example, in Malta, due to the small well-defined population, there was confidence that all deaths had been identified.

In some countries all national databases use the same unique ID number (for example Finland). So, identifying a child in the National Vital Statistics meant that there was confidence that any hospital stays up to ten years of age would also be identified. For other registries, as not all children were likely to be admitted to hospital, each case was searched for in, not only the in-patient hospital database (which included the mothers visit for the birth), but also any other health care databases (such as out-patient, primary-care or prescription databases) for longer than the ten years of follow-up in the study. The lack of information in any health care database was judged to mean a non-match. Sensitivity analysis was performed to assess if there were differences in results if the non-matches were included.

For the education data, all children known to be alive were assumed to be included in the National Education Databases and therefore any case not identified was assumed to be a non-match.

Syntax scripts were developed centrally by St George’s, University of London (SGUL) to evaluate the accuracy of the linkage and identify any factors leading to missed links (for example deaths within the first week of life). For each registry, the proportion of births in any single year of data that have not been linked is calculated and the data from any year with less than 85% of cases linked will be excluded from further analyses. Secondly, the quality of linked data items was also evaluated: a variable that was >20% missing in a year would be excluded from any analysis in which it featured; and variables that were recorded by both the CA registry and the linked database would be compared for agreement, by year. In general, it was found that data quality was poorer in the earlier years and tended to improve over time; however if data quality fluctuated across the years, then only the longest consecutive period where quality was above the threshold would be analysed.

## Statistical Analysis

Protocols and syntax scripts are developed centrally to create aggregate data and perform specific analyses on the individual cases in each standardised data set in STATA (Version 13 and upwards). This allows each register to submit aggregated data and analytical results (e.g. Kaplan-Meier estimates, hazard ratios and confidence intervals), rather than individual case data, to the EUROlinkCAT CRR at UU, UK using a secure web platform. UU collates the aggregate data and results and provides these data to the researchers responsible for the different analyses and publications. Multi-centre European analyses will be performed by combining the individual registries’ aggregated data and analytic results, using meta-analytic techniques. Additional work is required to develop suitable models for combining survival data from several registries when the sample sizes are very small as observed in many registries.

## Small Number Restrictions (Statistical Disclosure Control)

Four countries have limitations on the release of aggregate data and analytic results if the numbers of births involved are very small (generally under eight births). This situation arises in many analyses involving specific CAs, as CAs are rare, with some affecting less than 1 in 10,000 livebirths. Solutions to enable the maximum amount of data to be included in all multi-centre European analyses varied according to country. The Northern Netherlands released data if all exported results were rounded to the nearest 5. Rounding all frequencies ensures that original numbers cannot be inferred. For Denmark, a few named researchers at SGUL and UU were allowed access to the aggregate data for the purpose of collating and including in pooled-analysis, on condition that it was securely stored and processed; that any individual results involving fewer than five people were not released; and that personal identification was not possible from any released results. The SAIL databank (Wales) provided data to the CRR with the requirement that aggregate data on fewer than five people were not released and could not be calculated from any information in the public domain. The registry from Antwerp, Belgium could not release any information on three or fewer cases.

## Patient and Public Involvement

A series of focus groups has been held in different European countries involving parents with a child with one of four pre-defined CAs with different health problems covering learning difficulties, physical disabilities, visible defects and non-visible defects with higher mortality. The four anomalies selected were: CHD requiring surgery (referred to as severe CHD – a usually non-visible defect with high mortality), cleft lip (CL; a visible defect often with speech problems), spina bifida (SB; a physical disability with associated incontinence problems) and Down syndrome (DS; Trisomy 21; a visible defect with learning difficulties and often associated with CHD). The focus groups have investigated parental experiences of having a child with one of the above anomalies and assessed parental research priorities ADD when paper published.

In addition, a European survey concerning the diagnosis, medical care, education and everyday life will be distributed to parents across Europe with children with the same four CAs as described above. Registries will ensure the questions in the survey are appropriate for their country (for example the provision of health services, given how this differs in various European countries) and will translate the survey into their native language with back translation to confirm the accuracy of the translation. The aim is for the survey to be distributed via social media by parent support groups across Europe to engage with a wide spectrum of parents.

# Discussion

The aggregate data and results from the CRR in EUROlinkCAT will provide important information on the survival, morbidity and education of children born with a CA in Europe. Researchers in each CA registry will be encouraged to also perform specific local analysis, in order to fully exploit the research potential of linked datasets. The establishment of a method of standardising data from each registry linkage into a CDM provides valuable infrastructure enabling future multi-national studies to be performed in an efficient manner and new registries to become involved.

The strength of this study is that the researchers are a multidisciplinary group, many of whom have collaborated successfully for many years through being members of EUROCAT. In addition, EUROlinkCAT is able to build on all the standardisation procedures already established in EUROCAT. The implementation of a CDM enables the same centrally developed syntax script to be run in all the different registries which is efficient and also ensures standardisation of analysis across the registries. The use of a reference population when analysing health care data will aid in the identification of the source of differences between registries (for instance average LOS in hospitals will differ) and therefore enable us to better quantify the burden of disease attributable to CAs in each country. Comparisons of the accuracy of health care databases with respect to recording CA cases will be informative and enable improvements in those areas with less accurate data. We will also be developing recommendations on how to use the available health care data in an optimal way to provide information on children with CAs in areas without active CA registries.

One of the challenges of EUROlinkCAT is the ability of the CA registries to link their data to external data sources due to different local data information governance issues and the availability of suitable electronic health care databases. This requires flexibility in including registries in only specific sub-projects and acceptance that not all registries may be able to perform the linkages planned. In addition, some registries require support from other partners in all aspects of the project, including applying for ethics permissions, adapting protocols, standardising data and running statistical syntax scripts. The restriction of not being able to share individual case data and also aggregate data that might be disclosive or identifiable means that all analyses must be performed locally using a generic modelling strategy. This does limit the use of iterative procedures to explore data in detail. The major limitation to the study is that only specific areas in Europe are represented, with a lack of data in particular from Eastern Europe. Interpretation of differences across Europe is challenging as it will be essential to interpret results in the light of knowledge about the differences in health care and education practices across Europe.

The EUROlinkCAT project will enable important hypotheses concerning the survival, health and education of children with CAs in Europe to be investigated. The standardised methods and CDMs will all be available freely on the EUROlinkCAT website and will be available for use in future research projects to benefit from and build on this work, so as to enable other multi-centre European projects to exploit routine health care data available in Europe.

# Ethics and dissemination

The CA registries have the required ethics permissions and procedures for routine surveillance, data collection and transmission of anonymised data to the EUROCAT central database, according to national guidelines and they were required to submit evidence of these permissions to the EUROlinkCAT ethics portfolio. Local registries follow national legislation as to whether parental consent is needed for registration of babies with anomalies. Each registry was responsible for applying for and obtaining the additional ethics and other permissions (e.g. data sharing agreements) required to link and analyse their data for EUROlinkCAT. This was an extremely lengthy process in some countries as the original data collection did not include expectation or consent for the data to be used in research, and a new legal basis had to be established. Additional assurances and procedures were adopted by registries (e.g. publication of privacy notices) to ensure compliance with the General Data Protection Regulation (GDPR) which came into force on 25 April 2018 in EU countries. A checklist of minimum specifications for data storage/backup was completed by each registry. Three registries took over three years to get the ethics, legal basis, data protection, information governance and data sharing agreements in place. UU obtained ethics permission for the CRR.

Each registry participating in the focus groups with parents was responsible for ensuring the correct ethics approvals were in place. Similarly, the registries participating in the dissemination of the parents’ survey will be responsible for ensuring the necessary ethics permissions are obtained.

An Ethics and Data Protection Advisory Board (EDPB) consisting of three independent advisors with the relevant expertise monitor all ethical considerations in this project.

The CRR will be used for multiple studies and the results from these will be disseminated in peer reviewed papers and conference presentations. It is hoped that the experience gained with distributing the parents’ survey using parent support groups and social media will also lead to development of a framework to enable dissemination of results to be made more directly to parents. In addition, a series of reports will be written including recommendations for improving the collection and analysis of data on CAs in routinely collected data in the health care databases.

# References

1. Boyle, B., et al., *Estimating Global Burden of Disease due to congenital anomaly: an analysis of European data.* Arch Dis Child Fetal Neonatal Ed, 2018. **103**(1): p. F22-f28.

2. Zylbersztejn, A., et al., *Child mortality in England compared with Sweden: a birth cohort study.* Lancet, 2018. **391**(10134): p. 2008-2018.

3. Wang, H., et al., *Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.* Lancet, 2014. **384**(9947): p. 957-79.

4. Copeland, G.E. and R.S. Kirby, *Using birth defects registry data to evaluate infant and childhood mortality associated with birth defects: An alternative to traditional mortality assessment using underlying cause of death statistics.* Birth Defects Res A Clin Mol Teratol, 2007. **79**(11): p. 792-797.

5. Wu, J. and J.K. Morris, *The population prevalence of Down's syndrome in England and Wales in 2011.* Eur J Hum Genet, 2013. **21**(9): p. 1016-9.

6. Tennant, P.W., et al., *20-year survival of children born with congenital anomalies: a population-based study.* Lancet, 2010. **375**(9715): p. 649-56.

7. Brodwall, K., et al., *The five-year survival of children with Down syndrome in Norway 1994–2009 differed by associated congenital heart defects and extracardiac malformations.* Acta Paediatrica, 2018. **107**(5): p. 845-853.

8. Muranjan, M. and P. Vijayalakshmi, *The Unforeseen Toll of Birth Defects and their Economic Burden at a Tertiary Care Public Institute in Mumbai.* Ind J Pediatr, 2014. **81**(10): p. 1005-1009.

9. Simeone, R.M., et al., *Population-based study of hospital costs for hospitalizations of infants, children, and adults with a congenital heart defect, Arkansas 2006 to 2011.* Birth Defects Res A Clin Mol Teratol, 2015. **103**(9): p. 814-20.

10. Shetty, S., et al., *Length of stay and cost analysis of neonates undergoing surgery at a tertiary neonatal unit in England.* Ann R Coll Surg Engl, 2016. **98**(1): p. 56-60.

11. Fitzsimons, K.J., et al., *Hospital care of children with a cleft in England.* Arch Dis Child, 2013. **98**(12): p. 970-974.

12. Derrington, T.M., et al., *Racial/ethnic differences in hospital use and cost among a statewide population of children with Down syndrome.* Res Dev Disabil, 2013. **34**(10): p. 3276-87.

13. Dawson, A.L., et al., *Hospitalizations and associated costs in a population-based study of children with Down syndrome born in Florida.* Birth Defects Res A Clin Mol Teratol, 2014. **100**(11): p. 826-36.

14. Hook-Dufresne, D.M., et al., *The economic burden of gastroschisis: costs of a birth defect.* J Surg Res, 2015. **195**(1): p. 16-20.

15. Wehby, G.L., et al., *The effects of oral clefts on hospital use throughout the lifespan.* BMC Health Services Research, 2012. **12**(1): p. 58.

16. Hung, W.J., et al., *Cost of hospitalization and length of stay in people with Down syndrome: evidence from a national hospital discharge claims database.* Res Dev Disabil, 2011. **32**(5): p. 1709-13.

17. O'Toole, C., et al., *Parent-mediated interventions for promoting communication and language development in young children with Down syndrome.* The Cochrane database of systematic reviews, 2018. **10**(10): p. CD012089-CD012089.

18. Iyer, N.P., et al., *Outcome of fetuses with Turner syndrome: a 10-year congenital anomaly register based study.* J Matern Fetal Neonatal Med, 2012. **25**(1): p. 68-73.

19. Marino, B.S., et al., *Neurodevelopmental outcomes in children with congenital heart disease: evaluation and management: a scientific statement from the American Heart Association.* Circulation, 2012. **126**(9): p. 1143-72.

20. Wehby, G.L., et al., *Children with oral clefts are at greater risk for persistent low achievement in school than classmates.* Arch Dis Child, 2015. **100**(12): p. 1148-54.

21. Clausen, N.G., S. Kähler, and T.G. Hansen, *Systematic review of the neurocognitive outcomes used in studies of paediatric anaesthesia neurotoxicity.* Br J Anaesth, 2018. **120**(6): p. 1255-1273.

22. Boyd, P.A., et al., *Paper 1: The EUROCAT network—organization and processes†.* Birth Defects Res A Clin Mol Teratol, 2011. **91**(S1): p. S2-S15.

23. Greenlees, R., et al., *Paper 6: EUROCAT member registries: organization and activities.* Birth Defects Res A Clin Mol Teratol, 2011. **91 Suppl 1**: p. S51-s100.

24. Kinsner-Ovaskainen, A., et al., *A sustainable solution for the activities of the European network for surveillance of congenital anomalies: EUROCAT as part of the EU Platform on Rare Diseases Registration.* European Journal of Medical Genetics, 2018. **61**(9): p. 513-517.

25. Dolk, H., et al., *Detection and investigation of temporal clusters of congenital anomaly in Europe: seven years of experience of the EUROCAT surveillance system.* Eur J Epidemiol, 2015. **30**(11): p. 1153-1164.

26. Loane, M., et al., *Paper 4: EUROCAT statistical monitoring: Identification and investigation of ten year trends of congenital anomalies in Europe.* Birth Defects Res A Clin Mol Teratol, 2011. **91**(S1): p. S31-S43.

27. Salemi, J.L., et al., *The Accuracy of Hospital Discharge Diagnosis Codes for Major Birth Defects: Evaluation of a Statewide Registry With Passive Case Ascertainment.* J Public Health Manag Pract, 2016. **22**(3): p. E9-e19.

28. Wang, Y., P.K. Cross, and C.M. Druschel, *Hospital discharge data: can it serve as the sole source of case ascertainment for population-based birth defects surveillance programs?* J Public Health Manag Pract, 2010. **16**(3): p. 245-51.

29. Andrade, S.E., et al., *Validity of health plan and birth certificate data for pregnancy research.* Pharmacoepidemiol Drug Saf, 2013. **22**(1): p. 7-15.

30. Blais, L., et al., *Validity of congenital malformation diagnostic codes recorded in Québec's administrative databases.* Pharmacoepidemiol Drug Saf, 2013. **22**(8): p. 881-9.

31. Steele, A., et al., *A quality assessment of reporting sources for microcephaly in Utah, 2003 to 2013.* Birth Defects Res A Clin Mol Teratol, 2016. **106**(11): p. 983-988.

32. EUROCAT. *Guide 1.4*. 14/02/2018]; Available from: <http://www.eurocat-network.eu/aboutus/datacollection/guidelinesforregistration/guide1_4>.

33. Garne, E., et al., *Paper 5: Surveillance of multiple congenital anomalies: Implementation of a computer algorithm in European registers for classification of cases.* Birth Defects Res A Clin Mol Teratol, 2011. **91**(S1): p. S44-S50.

34. Herskind, A.M., et al., *Comparison of Late Mortality Among Twins Versus Singletons With Congenital Heart Defects.* The American Journal of Cardiology, 2017. **119**(10): p. 1680-1686.

35. Gnanendran, L., et al., *Neurodevelopmental outcomes of preterm singletons, twins and higher-order gestations: a population-based cohort study.* Arch Dis Child Fetal Neonatal Ed, 2015. **100**(2): p. F106-F114.

36. Wang, W., et al., *Outcomes of Congenital Diaphragmatic Hernia in One of the Twins.* Am J Perinatol, 2019. **36**(12): p. 1304-1309.

37. Martinka, D., et al., *Respiratory morbidity in late preterm twin infants.* Arch Gynecol Obstet, 2019. **300**(2): p. 337-345.

# Author contributions

JKM is the principal author and the project’s Scientific Coordinator; ML is the Data Coordinator; EG is the Clinical Coordinator; JD, AN, AP, JR and HdW are Steering Committee and Standardisation Committee members with JKM, ML and EG; IB and ALB are Steering Committee members; AR is a Standardisation Committee member; JT is the senior statistician; JG the research fellow; HC the project manager. All authors contributed to, read and approved the final manuscript.

# Collaborators

All below named members of the EUROlinkCAT Consortium have contributed to the development of the protocol with their knowledge and experience of the surveillance of congenital anomalies. Names are given in Consortium organisation numerical order:

Population Health Research Institute, St George’s, University of London, UK: Abigail Reid, Liz Limb, Gillian Briggs, Nicholas Connor

Faculty of Life and Health Sciences, Ulster University, Northern Ireland, UK: Joanne Given

Hospital Lillebaelt, Region Syddanmark, Denmark and Section of Epidemiology, University of Copenhagen, Denmark: Stine Kjaer Urhoj, Mads Damkjær, Christina Neergaard Pedersen

Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK: Svetlana V. Glinianaia

Emila Romagna Registry of Birth Defects (IMER), University of Ferrara, Italy: Gianni Astolfi, Annarita Armaroli; Neonatal Intensive Care Unit, IMER Registry, Department of Medical Sciences, University Hospital of Ferrara, Italy: Elia Ballardini; Territorial Care Service - Emilia Romagna Health Authority, Italy: Aurora Puccini

Klinika za dječje bolesti Zagreb, Croatia: Ljubica Boban

National Research Council-Institute of Clinical Physiology (Consiglio Nazionale delle Ricerche-Istituto di Fisiologia Clinica), Pisa, Italy: Michele Santoro, Alessio Coi, Silvia Baldacci, Lorena Mezzasalma

University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, the Netherlands: L. Renée Lutke, Nicole H.A. Siemensma-Mühlenberg

Public Health Wales National Health Service Trust, Wales, UK: David Tucker

Institut National de la Santé et de la Recherche Médicale, Paris, France: Babak Khoshnood, Nathalie Bertille, Nathalie Lelong, Makan Rahshenas

Rare Diseases Research Unit, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region, Valencia, Spain; Public Health and Preventive Medicine Department, University of València, Spain; Public Health Regional Health Administration (DG Salud Publica y Adicciones), Generalitat Valenciana, Valencia, Spain: Clara Cavero Carbonell, Óscar Zurriaga, Laia Barrachina Bonet, Laura García Villodre

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Poznań, Poland: Anna Jamry-Dziurla

Finnish Institute for Health and Welfare, Finland: Anna Heino, Sonja Kiuru-Kuhlefelt, Mika Gissler

OMNI-Net for Children International Charitable Fund, Rivne, Ukraine: Wladimir Wertelecki, Lyubov Yevtushok, Nataliia Zymak-Zakutnia, Diana Akhmedzhanova, Lyubov Ostapchuk, Oksana Tsizh, Serhii Lapchenko

Epidemiology Department, National Registry of Congenital Anomalies, National Institute of Health Doctor Ricardo Jorge: Carlos Matias Dias, Ausenda Machado, Ana João Santos, Liliana Antunes, Paula Braz

Register of Congenital Malformations, Centre Hospitalier Universitaire de La Réunion, Île de la Réunion, France: Hanitra Randrianaivo-Ranjatoelina, Benedicte Bertaut Nativel

Provinciaal Instituut voor Hygiëne (PIH), Antwerp, Belgium: Vera Nelen, Guy Thys, Elly Den Hond

Departamento de Salud Gobierno Vasco, Basque Country, Spain: Olatz Mokoroa Carollo

Swansea University, Wales, UK: Daniel Thayer, Ieuan Scanlon, Sue Jordan

Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway and Division of Mental and Physical Health Norwegian Institute of Public Health, Bergen, Norway: Kari Klungsøyr

Directorate for Health Information and Research, Malta: Miriam Gatt

# Funding statement

This project has received funding from the European Union’s Horizon 2020 Research and Innovation programme under grant agreement No 733001 for 5 years: 1st January 2017 to 31st December 2021.

# Data statement

The standardised methods and common data models will all be available freely on the EUROlinkCAT website. Requests for collaboration to analyse data from the study dataset are encouraged and should be addressed to the EUROlinkCAT Management Team, by contacting JKM. Interactive results tables will be accessible on the EUROlinkCAT website (<https://www.eurolinkcat.eu/>) later in the study.

# Competing interests statement

The authors declare that they have no competing interests.

# Figure legends

Figure 1: Structure of mortality and EUROCAT data used for analyzing children’s survival

Figure 2: Structure of hospital admissions, prescription data and EUROCAT data used for analyzing children’s morbidity